Source:http://linkedlifedata.com/resource/pubmed/id/20037466
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
21
|
| pubmed:dateCreated |
2009-12-29
|
| pubmed:grant | |
| pubmed:commentsCorrections | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Nov
|
| pubmed:issn |
1555-8576
|
| pubmed:author | |
| pubmed:issnType |
Electronic
|
| pubmed:volume |
8
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
2010-2
|
| pubmed:meshHeading | |
| pubmed:year |
2009
|
| pubmed:articleTitle |
Target validation using Phase 0 clinical trials: Promises and pitfalls.
|
| pubmed:affiliation |
Department of Investigational Cancer Therapeutics (Phase I Program), The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
|
| pubmed:publicationType |
Journal Article,
Comment,
Research Support, N.I.H., Extramural
|